QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN's Clinical Insights (QCI) platform has surpassed three million analyzed cases, reflecting a remarkable annual growth rate of over 35%, equivalent to 700,000 new cases. This software has outperformed competitors, analyzing five times more cases than other offerings. QCI integrates advanced Augmented Molecular Intelligence, enabling healthcare providers to enhance NGS testing reliability. QIAGEN aims to continue expanding its comprehensive solutions to meet the growing demand in the genetic analysis sector.
QIAGEN N.V. (NYSE: QGEN) will release its second quarter 2022 results on Wednesday, July 27, after 22:05 Frankfurt time. A conference call is scheduled for Thursday, July 28, at 15:30 Frankfurt time. Participants can join the call via callback connection, phone, or audio webcast. The company provides innovative solutions for molecular diagnostics and life sciences, serving over 500,000 customers globally. For further details, visit qiagen.com.
Relation Therapeutics has successfully raised $25 million in a seed financing round led by DCVC and Magnetic Ventures. The new capital will help expand its platform that integrates active-graph machine learning with single-cell analysis to accelerate drug discovery, targeting diseases with limited treatment options.
Dr. David Roblin and Dr. Lindsay Edwards have joined the company as CEO and CTO, respectively. The funding aims to enhance the understanding of disease biology and improve therapeutic outcomes.
QIAGEN (NYSE: QGEN) receives validation from the CDC for its QIAcuity digital PCR system for wastewater surveillance, marking a shift from traditional qPCR methods. This endorsement allows public health labs to utilize QIAcuity for detecting 30 pathogens, including SARS-CoV-2. Previously, QIAcuity was adopted in public health labs across 70% of U.S. states, enabling rapid results in just two hours. The CDC will now exclusively accept data from QIAcuity and another approved digital PCR platform, reinforcing QIAGEN's role in infectious disease monitoring and expanding its applications beyond COVID-19.
QIAGEN has launched its QIAwave nucleic-acid extraction kits, achieving a 35% lower environmental impact compared to standard kits. The products are the first in the industry to receive the ACT Environmental Impact Factor Label from My Green Lab. QIAGEN plans to enhance its sustainability efforts by collaborating with My Green Lab and aims to reduce plastic waste by 9% in 2022, after a 9.6% reduction in 2021. The company is committed to achieving net-zero carbon emissions by 2050.
QIAGEN has launched the QIAstat-Dx Rise, an advanced automated syndromic testing system receiving CE-marking, enabling up to 56 tests in an eight-hour shift. The system enhances the capacity for detecting multiple pathogens simultaneously, crucial for high-demand medical facilities. Key updates include an expanded QIAstat-Dx Respiratory SARS-CoV-2 Panel that now tests for 23 pathogens, including Chlamydophila pneumoniae, and a new Gastrointestinal Panel with improved performance. Additionally, a software update enhances cybersecurity and connectivity for the QIAstat-Dx systems.
QIAGEN has acquired a 96% stake in BLIRT SA, enhancing its capabilities in recombinant enzymes and molecular biology reagents. BLIRT, based in Poland, specializes in producing essential proteins and enzymes for diagnostics, generating under $10 million in sales in 2021. This acquisition aims to bolster QIAGEN's sample technologies business, expand global production, and enhance R&D capacities. The deal is expected to close in Q2 2022 and will not materially impact QIAGEN's financial outlook for the year, as previously stated.
QIAGEN N.V. announced Dr. Eva Pisa as a proposed new member of the Supervisory Board, enhancing leadership in the Life Science and Molecular Diagnostics sectors. All current board members will stand for re-election at the Annual General Meeting scheduled for June 23, 2022, in Venlo, Netherlands. Dr. Pisa's experience includes roles at Sangtec Molecular Diagnostics and Roche Diagnostics, offering valuable insights into health diagnostics. This strategic move aligns with QIAGEN's commitment to value creation for stakeholders in the Life Science and Molecular Diagnostics markets.
QIAGEN has announced the availability of its NeuMoDx HSV 1/2 Quant Assay for detecting herpes simplex virus type 1 and 2, following its CE-IVD certification. This assay enhances QIAGEN's offerings in viral load monitoring, particularly for immunocompromised patients, now totaling 15 CE-IVD assays for the NeuMoDx systems. The new assay is critical for organ transplant patients, addressing significant mortality risks from herpesvirus infections. QIAGEN also plans to launch additional assays in 2022, including tests for HHV-6 and reformulated EBV assays.
QIAGEN N.V. reported a strong Q1 2022, with net sales growing 11% to $628.4 million, exceeding the forecast of at least 7% growth. The company experienced a 14% rise in non-COVID sales and 18% growth in COVID-related products. Adjusted diluted EPS rose to $0.80, surpassing the expected $0.72. QIAGEN has raised its full-year net sales outlook to at least $2.12 billion and reaffirmed double-digit growth in non-COVID product lines. Despite anticipated sales declines in COVID products due to market volatility, QIAGEN remains committed to ongoing investments in its growth pillars.